{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:20:05Z","timestamp":1793391605449,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00125-016-3956-x","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T05:12:31Z","timestamp":1461561151000},"page":"1333-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":258,"title":["SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?"],"prefix":"10.1007","volume":"59","author":[{"given":"Naveed","family":"Sattar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren L.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"3956_CR1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"The Emerging Risk Factors Collaboration","year":"2010","unstructured":"The Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215\u20132222","journal-title":"Lancet"},{"key":"3956_CR2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765\u20131772","journal-title":"Lancet"},{"key":"3956_CR3","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","unstructured":"The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559","journal-title":"N Engl J Med"},{"key":"3956_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","volume":"357","author":"PD Home","year":"2007","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2007) Rosiglitazone evaluated for cardiovascular outcomes\u2014an interim analysis. N Engl J Med 357:28\u201338","journal-title":"N Engl J Med"},{"key":"3956_CR5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"3956_CR6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"3956_CR7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) EXAMINE: alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335","journal-title":"N Engl J Med"},{"key":"3956_CR8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242","journal-title":"N Engl J Med"},{"key":"3956_CR9","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247\u20132257","journal-title":"N Engl J Med"},{"key":"3956_CR10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang B, Zhong J, Lin H et al (2013) Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 15:737\u2013749","journal-title":"Diabetes Obes Metab"},{"key":"3956_CR11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","volume":"166","author":"SP Marso","year":"2013","unstructured":"Marso SP, Poulter NR, Nissen SE et al (2013) Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 166:823\u2013830","journal-title":"Am Heart J"},{"key":"3956_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2015","unstructured":"Madsbad S (2015) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18:317\u2013332","journal-title":"Diabetes Obes Metab"},{"key":"3956_CR13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jdiacomp.2012.12.004","volume":"27","author":"JN Basile","year":"2013","unstructured":"Basile JN (2013) The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabet Complications 27:280\u2013286","journal-title":"J Diabet Complications"},{"key":"3956_CR14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658\u2013666","journal-title":"Lancet"},{"key":"3956_CR15","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"88","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 88:2981\u20132997","journal-title":"JAMA"},{"key":"3956_CR16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZI Cherney","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587\u2013597","journal-title":"Circulation"},{"key":"3956_CR17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","volume":"2","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Gerstein HC, Holman RR, Pfeffer MA (2014) Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2:843\u2013851","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3956_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2014","unstructured":"Shah AD, Langenberg C, Rapsomaniki E et al (2014) Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people. Lancet Diabetes Endocrinol 3:105\u2013113","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3956_CR19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","volume":"313","author":"CA Emdin","year":"2015","unstructured":"Emdin CA, Rahimi K, Neal B et al (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603\u2013615","journal-title":"JAMA"},{"key":"3956_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.2013.774372","volume":"22","author":"WN Washburn","year":"2013","unstructured":"Washburn WN, Poucher SM (2013) Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22:463\u2013486","journal-title":"Expert Opin Investig Drugs"},{"key":"3956_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J 166:217\u2013223","journal-title":"Am Heart J"}],"updated-by":[{"DOI":"10.1007\/s00125-016-3987-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000}}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-3956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-016-3956-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-016-3956-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:16:44Z","timestamp":1553627804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-016-3956-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["3956"],"URL":"https:\/\/doi.org\/10.1007\/s00125-016-3956-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00125-016-3987-3","asserted-by":"object"}]},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]}}}